ArticlePharmacology research & perspectives2018
Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations.
Article in Pharmacology research & perspectives, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04758442 (Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology: a Nomogram Based on a Bayesian Population Model to Predict Initial Dosage of Vancomycin
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Updated antimicrobial dosing recommendations for obese patients.Antimicrobial agents and chemotherapy · 2024Pooled it
- Article
- Guideline-informed vancomycin therapeutic drug monitoring indications in an adult intensive care unit: a retrospective descriptive study.BMC anesthesiology · 2026Article
- Evaluating Bayesian Vancomycin Dosage Adjustment in Neonates: A Simulation-Based Virtual TDM Study.Clinical pharmacokinetics · 2026Article
- Vancomycin resistance in gram-positive infections: evolutionary strategies of survival.Archives of microbiology · 2026Review
- Novel Yunaconitine Derivatives as Protein Tyrosine Phosphatase 1B Inhibitors and Radical Scavenger: Design, Synthesis, in Vitro Cellular Evaluation, and Molecular Docking Study.Chemistry & biodiversity · 2026Article
- Evaluation of the Effect of Mechanical Ventilation on the Pharmacokinetic Parameters of Vancomycin in Intensive Care Patients: A Prospective Cohort Study.Journal of research in pharmacy practice · 2026Article
- Analysis of age-specific adverse events with vancomycin: a real-world pharmacovigilance study based on the FAERS database.International journal of surgery (London, England) · 2025Article
- Electrochemical biosensors for vancomycin monitoring in blood: advances, strategies, and future perspectives.RSC advances · 2025Review
- Towards precision dosing of vancomycin in patients with allogeneic hematopoietic stem cell transplantation: a comparison of published population pharmacokinetic models.Antimicrobial agents and chemotherapy · 2025Article
- Predicting Vancomycin Clearance in Neonates and Infants by Integrating Machine Learning and Metabolomics With Population Pharmacokinetics.Clinical and translational science · 2025Article
- DeepTDM: Deep Learning-Based Prediction of Sequential Therapeutic Drug Monitoring Levels of Vancomycin.IEEE journal of translational engineering in health and medicine · 2025Article
- Predicting the exposure of mycophenolic acid in children with autoimmune diseases using a limited sampling strategy: A retrospective study.Clinical and translational science · 2025Article
- Interinstitutional Comparison of Vancomycin Area Under the Concentration-Time Curve Estimation in Korea: Need for Standardized Operational Protocols for Therapeutic Drug Monitoring Consultation.Annals of laboratory medicine · 2025Article
- Dynamic interaction of antibiotic resistance between plant microbiome and organic fertilizers: sources, dissemination, and health risks.World journal of microbiology & biotechnology · 2024Review
- Vancomycin in Pediatric Patients with Cystic Fibrosis: Dose Optimization Using Population Pharmacokinetic Approach.European journal of drug metabolism and pharmacokinetics · 2024Article
- Automated calculation and reporting of vancomycin area under the concentration-time curve: a simplified single-trough concentration-based equation approach.Antimicrobial agents and chemotherapy · 2024Article
- Current and Ongoing Developments in TargetingMicroorganisms · 2024Review
- Clinical benefits of therapeutic drug monitoring of vancomycin therapy in patients with postoperative intracerebral hemorrhage: a retrospective cohort study.European journal of hospital pharmacy : science and practice · 2024Article
- A Deep Learning-Based Approach for Prediction of Vancomycin Treatment Monitoring: Retrospective Study Among Patients With Critical Illness.JMIR formative research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vancomycin is a fundamental antibiotic in the management of severe Gram-positive infections. Inappropriate vancomycin dosing is associated with therapeutic failure, bacterial resistance and toxicity. Therapeutic drug monitoring (TDM) is acknowledged as an important part of the vancomycin therapy management, at least in specific patient subpopulations, but implementation in clinical practice has been difficult because there are no consensus and agglutinator documents. The aims of the present work are to present an overview of the current knowledge on vancomycin TDM and population pharmacokinetic (PPK) models relevant to specific patient subpopulations. Based on three published international guidelines (American, Japanese and Chinese) on vancomycin TDM and a bibliographic review on available PPK models for vancomycin in distinct subpopulations, an analysis of evidence was carried out and the current knowledge on this topic was summarized. The results of this work can be useful to redirect research efforts to address the detected knowledge gaps. Currently, TDM of vancomycin presents a moderate level of evidence and practical recommendations with great robustness in neonates, pediatric and patients with renal impairment. However, it is important to investigate in other subpopulations known to present altered vancomycin pharmacokinetics (eg neurosurgical, oncological and cystic fibrosis patients), where evidence is still unsufficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.